Censavudine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Censavudine
Censavudine skeletal.svg
Censavudine ball-and-stick model.png
Clinical data
Synonyms4'-ethynylstavudine, festinavir
Legal status
Legal status
  • Investigational
Identifiers
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
NIAID ChemDB
CompTox Dashboard (EPA)
ECHA InfoCard100.225.812 Edit this at Wikidata
Chemical and physical data
FormulaC12H12N2O4
Molar mass248.235 g/mol g·mol−1
3D model (JSmol)

Censavudine (INN),[1] is an investigational new drug being developed by Bristol Myers-Squibb for the treatment of HIV infection. It was originally developed at Yale University.[2]

Renaming[edit]

Until 2013, censavudine has been known as festinavir, but the name was changed to avoid confusion with HIV protease inhibitors which all bear class suffix "–navir" (e.g. tipranavir, lopinavir, saquinavir etc.).

References[edit]

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed International Nonproprietary Names: List 110" (PDF). World Health Organization. pp. 409–410.
  2. ^ Alcorn, Keith (21 December 2010). "Bristol-Myers Squibb buys festinavir, new NRTI active against MDR HIV". aidsmap.com. aidsmap. Retrieved 24 June 2011.